XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.33

-8.6%

Jan 16 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (9272)	3/19/1999 1:10:00 PM
From: aknahow	Read Replies (2) of 17367

Interesting post by SLGonzalez. 5432 of 5432 Why Predicted Risk of Mortality model may be in use in PIII Meningo, which is why total mortality is key to the test of statistical significance in Xoma's relatively small N study. However, I am not in any way questioning looking at total mortality or its' absence in the both arms of trial. My question has been, and remains why include mortality in the treatment arm in the level required to end the trial? If mortality in the treatment arm had not been counted towards the total would the total required have remained the same, or been lower? If the total would have remained the same, it is obvious it made sense for XOMA's benefit to include them.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next